In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Prothena Corp Plc (NASDAQ:PRTA) reported that Price T Rowe Associates Inc has just bought a total of 3,514,610 of Prothena’s common stock, with the filing dated 2016-12-12.
The acquisition brings the total number of Prothena shares owned by Price T Rowe Associates Inc to a total of 3,514,610 representing a 10.1% stake in the company.
As an introduction to this one, Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion.
A quick look at some of Prothena Corp Plc (NASDAQ:PRTA)’s key stats shows that the company is currently trading for a market capitalization of $1.86 billion based on 34.49 million shares outstanding and a price per share, at last close, of $54.70.
Looking at insider activity, there hasn’t been too much recent activity, but there are a few legacy transactions worth noting.
Specifically, on 2014-08-07, Homan picked up 2,000 shares at a purchase price of $19.12. This brings their total holding to 2,000 shares as of the date of the filing.
On the sell side, the most recent transaction saw Selkoe unload 900 shares at a sale price of $63.59. This brings their total holding to 2,845, at the most recent count.
Prothena Corp is going thorugh a transitionary phase right now, and we’re going to be the company as things move forward to see if its progress aligns with these transactions. A Price T Rowe reinforcement is decidedly bullish, so we think it’s well worth keeping an eye on.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
